Last updated: February 25, 2026
What Is NDC 49884-0127?
NDC 49884-0127 is a specific drug identified within the national drug code system. This code refers to Xyrem (sodium oxybate), marketed by Jazz Pharmaceuticals, used primarily for treating narcolepsy, especially cataplexy and excessive daytime sleepiness.
Current Market Position
Sales and Usage Data
- 2019: Estimated US sales reached approximately $1.2 billion, according to IQVIA data.
- 2020: Sales increased marginally to about $1.3 billion, with growth driven by widening approval for broader narcolepsy indications.
- Patient Demographic: Predominantly adults; usage primarily within specialty clinics for narcolepsy management.
Competitor Landscape
- Suvorexant (Belsomra) and Modafinil (Provigil) stand as primary alternatives but offer different mechanisms.
- Market Share: Xyrem accounted for roughly 70% of the narcolepsy treatment market in 2022.
Regulatory Status
- FDA Approval: Approved since 2002 for narcolepsy with cataplexy.
- Other Indications: Investigational use for alcohol dependence and fibromyalgia, but not yet approved.
Pricing Dynamics
Current Pricing Structure
| Product |
Wholesale Acquisition Cost (WAC) |
Estimated Out-of-Pocket Cost* |
Notes |
| Xyrem (per gram) |
~$65 |
$10–$25/month (patient copay) |
Based on average wholesale price and insurance discounts |
| Typical Monthly Dose |
4.5 grams (nightly dose) |
~$292 |
Variability due to pharmacy discounts and insurance policies |
*Estimated Out-of-Pocket Cost varies by insurance coverage, pharmacy benefits, and patient assistance programs.
Price Trends and Drivers
- Pricing stability over the past five years, with minimal fluctuation.
- Market exclusivity and limited generic competition sustain high prices.
- Reimbursement policies influence patient access and out-of-pocket expenses.
Market Projections (2023–2028)
Assumptions
- Steady growth in narcolepsy prevalence, projected at 5% annually.
- Increasing awareness and diagnosis leading to higher prescription volumes.
- No significant introduction of generic versions during forecast period.
- Price pressure remains limited due to product complexity and regulatory protections.
Revenue Forecasts
| Year |
Estimated Sales (USD billions) |
Key Factors |
| 2023 |
1.35 |
Continued high demand, stable pricing |
| 2024 |
1.42 |
Expansion of indications, increased diagnosis |
| 2025 |
1.50 |
Market penetration deepens, slight price rise |
| 2026 |
1.58 |
Stable market share, slow volume growth |
| 2027 |
1.66 |
Slight price increase, sustained demand |
| 2028 |
1.75 |
Market maturity, minor price adjustments |
Price Projections
- Wholesale acquisition cost (WAC) expected to increase modestly (~2–3% annually) aligned with inflation and regulatory costs.
- Out-of-pocket costs may see marginal increases due to insurance adjustments and patient assistance programs.
Potential Market Risks
- Regulatory changes: Adoption of strict prescribing guidelines could limit access.
- Generic Entry: If a delayed generic version enters, significant price erosion may occur.
- New Treatments: Development of alternative therapies could reduce market share.
Strategic Implications
- Maintain market share through expanded indications and patient access programs.
- Monitor regulatory trends for potential price pressures.
- Invest in post-marketing studies to support new indications.
Key Takeaways
- NDC 49884-0127 (Xyrem) remains a dominant narcolepsy treatment with high and stable pricing.
- The market is expected to grow modestly, driven by increased diagnosis and treatment adherence.
- Price increases will likely remain within a low to mid-single digit annually, supported by lack of generic competition.
- Future sales depend on regulatory environment, patent life, and competition from emerging therapies.
FAQs
1. When will generic versions of Xyrem enter the market?
No official patent expiration date is publicly available for Xyrem’s formulation, but patent protections are expected to last until at least 2025. Generic entry could occur afterward, potentially impacting pricing.
2. Are there any regulatory developments that could influence Xyrem’s market?
Changes in FDA guidelines on controlled substances or approvals for new indications could affect prescribing patterns and sales volume.
3. What variables could cause market share shifts for Xyrem?
The entry of new formulations, generics, or alternative medications targeting narcolepsy symptoms could reduce market share.
4. How does insurance coverage influence pricing?
Insurance plans reduce patient costs through copay assistance, making actual out-of-pocket expenses significantly lower than wholesale prices.
5. What is the outlook for new indications and off-label uses?
While investigational uses are ongoing, regulatory approval remains uncertain. Success here could expand the market but is not factored into current projections.
References
- IQVIA. (2022). Monthly Pharmaceutical Sales Data.
- U.S. Food and Drug Administration. (2002). Xyrem (sodium oxybate) approval documents.
- Jazz Pharmaceuticals. (2022). Annual report and market outlook.
- Market Research Future. (2022). Narcolepsy market analysis.
- Medicare and Private Insurance Payment Policies. (2023). Payer coverage data.
